The effects of statins on osteoarthritis structural progression: Another glimpse of the Holy Grail?

Annals of the Rheumatic Diseases

Volumn 71, Issue 5, 2012, Pages 633-634

  Conaghan, Philip G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; COMPACTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERSTITIAL COLLAGENASE; SIMVASTATIN; STROMELYSIN;

ANTIINFLAMMATORY ACTIVITY; CARTILAGE CELL; CELL AGING; CLINICAL RESEARCH; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; DRUG TARGETING; EDITORIAL; HUMAN; IMMUNOMODULATION; METABOLIC SYNDROME X; MORTALITY; NONHUMAN; OBESITY; OSTEOARTHRITIS; PRIORITY JOURNAL; RISK FACTOR; T LYMPHOCYTE ACTIVATION;

FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE;

EID: 84859480250     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201135     Document Type: Editorial

References (29)

1. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55. (Pubitemid 37500619)
2. Conaghan PG, Dickson J, Grant RL. Care and management of osteoarthritis in adults: summary of NICE guidance. BMJ 2008;336:502-3. (Pubitemid 351347417)
3. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010;18:476-99.
4. Berenbaum F. The quest for the Holy Grail: a disease-modifying osteoarthritis drug. Arthritis Res Ther 2007;9:111.
5. Saag KG. Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not? Ann Rheum Dis 2008;67:1358-9.
6. Clockaerts S, Van Osch GJ, Bastiaansen-Jenniskens YM, et al. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. Ann Rheum Dis 2012;71:642-47.
7. Abeles AM, Pillinger MH. Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis Rheum 2006;54:393-407. (Pubitemid 43228614)
8. Baker JF, Walsh P, Mulhall KJ. Statins: a potential role in the management of osteoarthritis? Joint Bone Spine 2011;78:31-4.
9. Lazzerini PE, Capecchi PL, Selvi E, et al. Statins and the joint: multiple targets for a global protection? Semin Arthritis Rheum 2011;40:430-46.
10. Attur M, Samuels J, Krasnokutsky S, et al. Targeting the synovial tissue for treating osteoarthritis (OA): where is the evidence? Best Pract Res Clin Rheumatol 2010;24:71-9.
11. Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011;7:33-42.
12. Kwan Tat S, Lajeunesse D, Pelletier JP, et al. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol 2010;24:51-70.
13. Katz JD, Agrawal S, Velasquez M. Getting to the heart of the matter: osteoarthritis takes its place as part of the metabolic syndrome. Curr Opin Rheumatol 2010;22:512-19.
14. Nüesch E, Dieppe P, Reichenbach S, et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011;342:d1165.
15. Findlay DM. Vascular pathology and osteoarthritis. Rheumatology (Oxford) 2007;46:1763-8. (Pubitemid 350168289)
16. Conaghan PG, Vanharanta H, Dieppe PA. Is progressive osteoarthritis an atheromatous vascular disease? Ann Rheum Dis 2005;64:1539-41. (Pubitemid 41532034)
17. Wu YS, Hu YY, Yang RF, et al. The matrix metalloproteinases as pharmacological target in osteoarthritis: statins may be of therapeutic benefit. Med Hypotheses 2007;69:557-9. (Pubitemid 47043272)
18. Lazzerini PE, Capecchi PL, Nerucci F, et al. Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture. Ann Rheum Dis 2004;63:867-9. (Pubitemid 38850462)
19. Barter MJ, Hui W, Lakey RL, et al. Lipophilic statins prevent matrix metalloproteinase-mediated cartilage collagen breakdown by inhibiting protein geranylgeranylation. Ann Rheum Dis 2010;69:2189-98.
20. Sverdrup FM, Yates MP, Vickery LE, et al. Protein geranylgeranylation controls collagenase expression in osteoarthritic cartilage. Osteoarthr Cartil 2010;18:948-55.
21. Yudoh K, Karasawa R. Statin prevents chondrocyte aging and degeneration of articular cartilage in osteoarthritis (OA). Aging (Albany NY) 2010;2:990-8.
22. Akasaki Y, Matsuda S, Nakayama K, et al. Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation. Osteoarthr Cartil 2009;17:235-43.
23. Aktas E, Sener E, Gocun PU. Mechanically induced experimental knee osteoarthritis benefits from anti-inflammatory and immunomodulatory properties of simvastatin via inhibition of matrix metalloproteinase-3. J Orthop Traumatol 2011;12:145-51.
24. Hunter DJ, Le Graverand MP, Eckstein F. Radiologic markers of osteoarthritis progression. Curr Opin Rheumatol 2009;21:110-17.
25. Zhang Y, Niu J, Felson DT, et al. Methodologic challenges in studying risk factors for progression of knee osteoarthritis. Arthritis Care Res (Hoboken) 2010;62:1527-32.
26. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA 2011;305:822-3.
27. Glymour MM. When bad genes look good - APOE*E4, cognitive decline, and diagnostic thresholds. Am J Epidemiol 2007;165:1239-46. (Pubitemid 47234334)
28. Bierma-Zeinstra SM, Koes BW. Risk factors and prognostic factors of hip and knee osteoarthritis. Nat Clin Pract Rheumatol 2007;3:78-85.
29. Beattie MS, Lane NE, Hung YY, et al. Association of statin use and development and progression of hip osteoarthritis in elderly women. J Rheumatol 2005;32:106-10. (Pubitemid 40092600)